

# Erik de Vries

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5705170/publications.pdf>

Version: 2024-02-01

121  
papers

4,459  
citations

159585

30  
h-index

118850

62  
g-index

125  
all docs

125  
docs citations

125  
times ranked

6036  
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation and testâ€“retest repeatability performance of parametric methods for [ <sup>11</sup> C]UCB-J PET. EJNMMI Research, 2022, 12, 3.	2.5	3
2	A single dose of ketamine cannot prevent protracted stress-induced anhedonia and neuroinflammation in rats. Stress, 2022, 25, 145-155.	1.8	2
3	Pharmacokinetic Modeling of [ <sup>11</sup> C]GSK-189254, PET Tracer Targeting H <sub>3</sub> Receptors, in Rat Brain. Molecular Pharmaceutics, 2022, 19, 918-928.	4.6	1
4	The effect of lesion filling on brain network analysis in multiple sclerosis using structural magnetic resonance imaging. Insights Into Imaging, 2022, 13, 63.	3.4	2
5	Immune Activation in Pregnant Rats Affects Brain Glucose Consumption, Anxiety-like Behaviour and Recognition Memory in their Male Offspring. Molecular Imaging and Biology, 2022, 24, 740-749.	2.6	3
6	Quantitative assessment of myelin density using [ <sup>11</sup> C]MeDAS PET in patients with multiple sclerosis: a first-in-human study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3492-3507.	6.4	6
7	Potential PET tracers for imaging of tumor-associated macrophages. EJNMMI Radiopharmacy and Chemistry, 2022, 7, 11.	3.9	11
8	Clinical Validity of <sup>18</sup> F-Fluoro- <sup>17</sup> β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. Journal of Clinical Oncology, 2022, 40, 3642-3652.	1.6	21
9	Diffusion-derived parameters in lesions, peri-lesion and normal-appearing white matter in multiple sclerosis using tensor, kurtosis and fixel-based analysis. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 2095-2106.	4.3	2
10	Impact of an Adenosine A <sub>2A</sub> Receptor Agonist and Antagonist on Binding of the Dopamine D <sub>2</sub> Receptor Ligand [ <sup>11</sup> C]raclopride in the Rodent Striatum. Molecular Pharmaceutics, 2022, 19, 2992-3001.	4.6	2
11	Myelin quantification with MRI: A systematic review of accuracy and reproducibility. NeuroImage, 2021, 226, 117561.	4.2	67
12	Kinetics and 28-day testâ€“retest repeatability and reproducibility of [ <sup>11</sup> C]UCB-J PET brain imaging. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1338-1350.	4.3	14
13	Serial [ <sup>18</sup> F]-FDHT-PET to predict bicalutamide efficacy in patients with androgen receptor positive metastatic breast cancer. European Journal of Cancer, 2021, 144, 151-161.	2.8	13
14	Abstract PS3-05: Value of [ <sup>18</sup> F]-FES-PET to solve clinical dilemmas in breast cancer patients: A retrospective study. , 2021, , .		0
15	Allosteric Interactions between Adenosine A <sub>2A</sub> and Dopamine D <sub>2</sub> Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging. International Journal of Molecular Sciences, 2021, 22, 1719.	4.1	17
16	Value of <sup>18</sup> F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study. Journal of Nuclear Medicine, 2021, 62, 1214-1220.	5.0	21
17	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4369-4376.	6.4	23
18	Is cyclooxygenaseâ€“1 involved in neuroinflammation?. Journal of Neuroscience Research, 2021, 99, 2976-2998.	2.9	28

#	ARTICLE	IF	CITATIONS
19	Prenatal fluoxetine impairs non-hippocampal but not hippocampal memory in adult male rat offspring. <i>Neuropharmacology</i> , 2021, 197, 108751.	4.1	4
20	Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16 $\beta$ -18F-Fluoro-5 $\alpha$ -Dihydrotestosterone. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1140-1145.	5.0	7
21	The dual hit hypothesis of schizophrenia: Evidence from animal models. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 131, 1150-1168.	6.1	36
22	Analyzing the Estrogen Receptor Status of Liver Metastases with [18F]-FES-PET in Patients with Breast Cancer. <i>Diagnostics</i> , 2021, 11, 2019.	2.6	4
23	PET and SPECT Imaging of Steroid Hormone Receptors in the Brain. , 2021, , 483-520.		2
24	Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 $\beta$ -[18F]Fluoro-17 $\beta$ -Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, e165-e167.	1.3	7
25	Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. <i>European Journal of Cancer</i> , 2020, 126, 11-20.	2.8	39
26	Modeling of [18F]FEOBV Pharmacokinetics in Rat Brain. <i>Molecular Imaging and Biology</i> , 2020, 22, 931-939.	2.6	2
27	Therapy-Induced Changes in CXCR4 Expression in Tumor Xenografts Can Be Monitored Noninvasively with N-[11C]Methyl-AMD3465 PET. <i>Molecular Imaging and Biology</i> , 2020, 22, 883-890.	2.6	6
28	Image Quality and Interpretation of [18F]-FES-PET: Is There any Effect of Food Intake?. <i>Diagnostics</i> , 2020, 10, 756.	2.6	4
29	Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degradar, in Healthy Post-Menopausal Women. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 675-689.	1.6	22
30	Monitoring the Crosstalk Between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 with PET. <i>Molecular Imaging and Biology</i> , 2020, 22, 1218-1225.	2.6	3
31	Delayed effects of a single-dose whole-brain radiation therapy on glucose metabolism and myelin density: a longitudinal PET study. <i>International Journal of Radiation Biology</i> , 2020, 96, 1135-1143.	1.8	1
32	Application of PET Tracers in Molecular Imaging for Breast Cancer. <i>Current Oncology Reports</i> , 2020, 22, 85.	4.0	28
33	Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1355-1360.	5.0	32
34	The Acute and Early Effects of Whole-Brain Irradiation on Glial Activation, Brain Metabolism, and Behavior: a Positron Emission Tomography Study. <i>Molecular Imaging and Biology</i> , 2020, 22, 1012-1020.	2.6	8
35	Chronic harmine treatment has a delayed effect on mobility in control and socially defeated rats. <i>Psychopharmacology</i> , 2020, 237, 1595-1606.	3.1	8
36	Ovariectomy-induced depressive-like behavior and brain glucose metabolism changes in female rats are not affected by chronic mild stress. <i>Psychoneuroendocrinology</i> , 2020, 115, 104610.	2.7	20

#	ARTICLE	IF	CITATIONS
37	Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study. <i>EJNMMI Research</i> , 2020, 10, 40.	2.5	13
38	Therapeutic effects of dietary intervention on neuroinflammation and brain metabolism in a rat model of photothrombotic stroke. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 36-46.	3.9	8
39	Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. <i>Molecular Neurobiology</i> , 2019, 56, 3295-3312.	4.0	449
40	Clinical-grade N-(4-[18F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 15.	3.9	15
41	<sup>99m</sup> Tc-HYNIC-IL-2 scintigraphy to detect acute rejection in lung transplantation patients: a proof-of-concept study. <i>EJNMMI Research</i> , 2019, 9, 41.	2.5	7
42	Long-term environmental modifications affect BDNF concentrations in rat hippocampus, but not in serum. <i>Behavioural Brain Research</i> , 2019, 372, 111965.	2.2	13
43	Repeated social defeat induces transient glial activation and brain hypometabolism: A positron emission tomography imaging study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 439-453.	4.3	19
44	Evaluation of exercise-induced modulation of glial activation and dopaminergic damage in a rat model of Parkinson's disease using [ <sup>11</sup> C]PBR28 and [ <sup>18</sup> F]FDOPA PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 989-1004.	4.3	35
45	Enhanced pulmonary uptake on 18F-FES-PET/CT scans after irradiation of the thoracic area: related to fibrosis?. <i>EJNMMI Research</i> , 2019, 9, 82.	2.5	10
46	Early <sup>18</sup> F-FDHT PET/CT as a predictor of treatment response in mCRPC treated with enzalutamide.. <i>Journal of Clinical Oncology</i> , 2019, 37, 232-232.	1.6	2
47	<sup>18</sup> F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1212-1218.	5.0	45
48	Anti-inflammatory effects of rice bran components. <i>Nutrition Reviews</i> , 2018, 76, 372-379.	5.8	15
49	Potential Therapeutic Applications of Adenosine A <sub>2A</sub> Receptor Ligands and Opportunities for A <sub>2A</sub> Receptor Imaging. <i>Medicinal Research Reviews</i> , 2018, 38, 5-56.	10.5	35
50	PET Imaging with S-[ <sup>11</sup> C]Methyl-L-Cysteine and L-[Methyl- <sup>11</sup> C]Methionine in Rat Models of Glioma, Glioma Radiotherapy, and Neuroinflammation. <i>Molecular Imaging and Biology</i> , 2018, 20, 465-472.	2.6	7
51	Sex steroid hormones and brain function: <sup>18</sup> F-PET imaging as a tool for research. <i>Journal of Neuroendocrinology</i> , 2018, 30, e12565.	2.6	42
52	Beneficial Effects of Whole Body Vibration on Brain Functions in Mice and Humans. <i>Dose-Response</i> , 2018, 16, 155932581881175.	1.6	32
53	Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study. <i>Oncotarget</i> , 2018, 9, 19836-19846.	1.8	13
54	In vivo evaluation of [ <sup>11</sup> C]preladenant positron emission tomography for quantification of adenosine A <sub>2A</sub> receptors in the rat brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 577-589.	4.3	19

#	ARTICLE	IF	CITATIONS
55	Improved GMP-compliant multi-dose production and quality control of 6-[ <sup>18</sup> F]fluoro-L-DOPA. EJNMMI Radiopharmacy and Chemistry, 2017, 1, 7.	3.9	15
56	In Vivo Evaluation of <sup>11</sup> C-Preladenant for PET Imaging of Adenosine A <sub>2A</sub> Receptors in the Conscious Monkey. Journal of Nuclear Medicine, 2017, 58, 762-767.	5.0	19
57	Initial Evaluation of an Adenosine A <sub>2A</sub> Receptor Ligand, <sup>11</sup> C-Preladenant, in Healthy Human Subjects. Journal of Nuclear Medicine, 2017, 58, 1464-1470.	5.0	23
58	Radiation Dosimetry of a Novel Adenosine A <sub>2A</sub> Receptor Radioligand [ <sup>11</sup> C]Preladenant Based on PET/CT Imaging and Ex Vivo Biodistribution in Rats. Molecular Imaging and Biology, 2017, 19, 289-297.	2.6	15
59	<sup>18</sup> F-FES PET Has Added Value in Staging and Therapy Decision Making in Patients With Disseminated Lobular Breast Cancer. Clinical Nuclear Medicine, 2017, 42, 612-614.	1.3	19
60	Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia. NeuroImage, 2017, 157, 209-218.	4.2	12
61	Contribution of neuroinflammation to changes in [ <sup>11</sup> C]flumazenil binding in the rat brain: Evaluation of the inflamed pons as reference tissue. Nuclear Medicine and Biology, 2017, 49, 50-56.	0.6	6
62	Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. Journal of Nuclear Medicine, 2017, 58, 1906-1912.	5.0	48
63	N-[ <sup>11</sup> C]Methyl-AMD3465 PET as a Tool for In Vivo Measurement of Chemokine Receptor 4 (CXCR4) Occupancy by Therapeutic Drugs. Molecular Imaging and Biology, 2017, 19, 570-577.	2.6	12
64	Effect of Preventive and Curative Fingolimod Treatment Regimens on Microglia Activation and Disease Progression in a Rat Model of Multiple Sclerosis. Journal of NeuroImmune Pharmacology, 2017, 12, 521-530.	4.1	6
65	Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. Journal of Psychopharmacology, 2017, 31, 1149-1165.	4.0	191
66	Evaluating [ <sup>11</sup> C]PBR28 PET for Monitoring Gut and Brain Inflammation in a Rat Model of Chemically Induced Colitis. Molecular Imaging and Biology, 2017, 19, 68-76.	2.6	13
67	Noninvasive monitoring of cancer therapy induced activated T cells using [ <sup>18</sup> F]FB-IL-2 PET imaging. Oncolmmunology, 2017, 6, e1248014.	4.6	51
68	Pharmacokinetic Analysis of <sup>11</sup> C-PBR28 in the Rat Model of Herpes Encephalitis: Comparison with [ <sup>11</sup> C]-PK11195. Journal of Nuclear Medicine, 2016, 57, 785-791.	5.0	21
69	PET/CT imaging of Mycobacterium tuberculosis infection. Clinical and Translational Imaging, 2016, 4, 131-144.	2.1	98
70	The combination of vitamins and omega-3 fatty acids has an enhanced anti-inflammatory effect on microglia. Neurochemistry International, 2016, 99, 206-214.	3.8	26
71	Recommendations and Technical Aspects of <sup>16</sup> α-[ <sup>18</sup> F]Fluoro- <sup>17</sup> β-Estradiol PET to Image the Estrogen Receptor In Vivo. Clinical Nuclear Medicine, 2016, 41, 844-851.	1.3	37
72	Isolation and <sup>111</sup> In-Labeling of Murine NK Cells for Assessment of Cell Trafficking in Orthotopic Lung Tumor Model. Molecular Pharmaceutics, 2016, 13, 1329-1338.	4.6	7

#	ARTICLE	IF	CITATIONS
73	Assessment of Estrogen Receptor Expression in Epithelial Ovarian Cancer Patients Using $^{18}\text{F}$ -Fluoro- $^{17}\beta$ -Estradiol PET/CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 50-55.	5.0	44
74	Dextrin-Based Nanomagnetogel: In Vivo Biodistribution and Stability. <i>Bioconjugate Chemistry</i> , 2015, 26, 699-706.	3.6	9
75	In vivo imaging of brain androgen receptors in rats: a [ $^{18}\text{F}$ ]FDHT PET study. <i>Nuclear Medicine and Biology</i> , 2015, 42, 561-569.	0.6	9
76	The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients. <i>British Journal of Cancer</i> , 2015, 112, 1617-1625.	6.4	18
77	Evaluation of [ $^{11}\text{C}$ ]CB184 for imaging and quantification of TSPO overexpression in a rat model of herpes encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1106-1118.	6.4	14
78	Positron emission tomography of tumour [ $^{18}\text{F}$ ]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1674-1681.	6.4	48
79	FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression.. <i>Journal of Clinical Oncology</i> , 2015, 33, 527-527.	1.6	2
80	[ $^{11}\text{C}$ ]5-HTP and microPET are Not Suitable for Pharmacodynamic Studies in the Rodent Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 118-125.	4.3	10
81	PET imaging of glucose metabolism, neuroinflammation and demyelination in the lysolecithin rat model for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1443-1452.	3.0	29
82	Neuroinflammation in bipolar disorder – A [ $^{11}\text{C}$ ]-( <i>R</i> )-PK11195 positron emission tomography study. <i>Brain, Behavior, and Immunity</i> , 2014, 40, 219-225.	4.1	176
83	PET imaging of focal demyelination and remyelination in a rat model of multiple sclerosis: comparison of [ $^{11}\text{C}$ ]MeDAS, [ $^{11}\text{C}$ ]CIC and [ $^{11}\text{C}$ ]PIB. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 995-1003.	6.4	47
84	PET imaging of demyelination and remyelination in the cuprizone mouse model for multiple sclerosis: A comparison between [ $^{11}\text{C}$ ]CIC and [ $^{11}\text{C}$ ]MeDAS. <i>NeuroImage</i> , 2014, 87, 395-402.	4.2	34
85	In Vivo Imaging of Brain Estrogen Receptors in Rats: A $^{18}\text{F}$ -Fluoro- $^{17}\beta$ -Estradiol PET Study. <i>Journal of Nuclear Medicine</i> , 2014, 55, 481-487.	5.0	29
86	PET Imaging of Disease Progression and Treatment Effects in the Experimental Autoimmune Encephalomyelitis Rat Model. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1330-1335.	5.0	15
87	Synthesis and Preclinical Evaluation of 2-(2-Furanyl)-7-[2-[4-[4-(2-[ $^{11}\text{C}$ ]methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7 <i>H</i> -pyrazolo[4,3- <i>g</i> ][1,2,4]triazol-5-yl]pyridine ([ $^{11}\text{C}$ ]Preladenant) as a PET Tracer for the Imaging of Cerebral Adenosine A <sub>2A</sub> Receptors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9204-9210.	6.4	29
88	Evaluation of [ $^{11}\text{C}$ ]Methyl-AMD3465 as a PET Tracer for Imaging of CXCR4 Receptor Expression in a C6 Glioma Tumor Model. <i>Molecular Pharmaceutics</i> , 2014, 11, 3810-3817.	4.6	30
89	Perinatal exposure to DOTC (di-n-octyltin dichloride) affects brain development. A study in rats using MRI (magnetic resonance imaging), [ $^{18}\text{F}$ ]FDG brain PET and genome wide gene expression profiling. <i>Reproductive Toxicology</i> , 2014, 48, 12-13.	2.9	0
90	Clozapine improves outcome and reduces neuroinflammation in a herpes encephalitis model. <i>Neurology Psychiatry and Brain Research</i> , 2014, 20, 14-15.	2.0	1

#	ARTICLE	IF	CITATIONS
91	[ <sup>99m</sup> Tc]O <sub>2</sub> -AMD3100 as a SPECT tracer for CXCR4 receptor imaging. <i>Nuclear Medicine and Biology</i> , 2013, 40, 507-517.	0.6	26
92	PET imaging of oestrogen receptors in patients with breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, e465-e475.	10.7	173
93	The Use of $^{18}\text{F}$ -FDG-PET/CT for Diagnosis and Treatment Monitoring of Inflammatory and Infectious Diseases. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-14.	3.3	198
94	<sup>18</sup> F-Fluorobenzoyl)Interleukin-2 for PET of Human-Activated T Lymphocytes. <i>Journal of Nuclear Medicine</i> , 2012, 53, 679-686.	5.0	88
95	PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 182-190.	5.0	136
96	In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O- <sup>125</sup> I-D-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging <sup>125</sup> I-Glucuronidase Activity in a Tumor/Inflammation Rodent Model. <i>Molecular Imaging</i> , 2012, 11, 7290.2011.00029.	1.4	9
97	15 Imaging Visualisation of Drug Target and Drug Effect. <i>European Journal of Cancer</i> , 2012, 48, 8.	2.8	1
98	Pharmacokinetic modelling of N-(4-[ <sup>18</sup> F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1551-1560.	6.4	31
99	Imaging of Cells and Nanoparticles: Implications for Drug Delivery to the Brain. <i>Pharmaceutical Research</i> , 2012, 29, 3213-3234.	3.5	18
100	Synthesis and Evaluation of <sup>99m</sup> Tc-Labelled Monoclonal Antibody 1D09C3 for Molecular Imaging of Major Histocompatibility Complex Class II Protein Expression. <i>Molecular Imaging and Biology</i> , 2011, 13, 930-939.	2.6	15
101	Guidelines for the labelling of leucocytes with <sup>99m</sup> Tc-HMPAO. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 842-848.	6.4	246
102	Synthesis and Optimization of the Labeling Procedure of <sup>99m</sup> Tc-Hynic-Interleukin-2 for In vivo Imaging of Activated T lymphocytes. <i>Molecular Imaging and Biology</i> , 2010, 12, 539-546.	2.6	33
103	1 Novel molecular imaging for early drug development. <i>European Journal of Cancer</i> , Supplement, 2010, 8, 9.	2.2	0
104	Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1801-1807.	5.0	515
105	[ <sup>11</sup> C]-DPA-713 and [ <sup>18</sup> F]-DPA-714 as New PET Tracers for TSPO: A Comparison with [ <sup>11</sup> C]-(R)-PK11195 in a Rat Model of Herpes Encephalitis. <i>Molecular Imaging and Biology</i> , 2009, 11, 386-98.	2.6	113
106	Evaluation of [ <sup>11</sup> C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. <i>Nuclear Medicine and Biology</i> , 2008, 35, 35-42.	0.6	115
107	PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders. <i>Current Pharmaceutical Design</i> , 2008, 14, 3297-3315.	1.9	105
108	PET Imaging of Steroid Receptor Expression in Breast and Prostate Cancer. <i>Current Pharmaceutical Design</i> , 2008, 14, 3020-3032.	1.9	32

#	ARTICLE	IF	CITATIONS
109	Nuclear Imaging of Hormonal Receptor Status in Breast Cancer: A Tool for Guiding Endocrine Treatment and Drug Development. <i>Current Cancer Drug Targets</i> , 2007, 7, 510-519.	1.6	12
110	Molecular imaging in metastatic breast cancer. <i>Cancer Metastasis - Biology and Treatment</i> , 2007, , 307-319.	0.1	3
111	Imaging of Cyclooxygenase-2 (COX-2) Expression: Potential Use in Diagnosis and Drug Evaluation. <i>Current Pharmaceutical Design</i> , 2006, 12, 3847-56.	1.9	47
112	Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders. <i>Current Clinical Pharmacology</i> , 2006, 1, 229-242.	0.6	20
113	Synthesis and evaluation of dopamine D3 receptor antagonist <sup>11</sup> C-GR218231 as PET tracer for P-glycoprotein. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1384-92.	5.0	20
114	Synthesis and in vivo evaluation of <sup>18</sup> F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1700-6.	5.0	51
115	Scintigraphic Imaging of HSVtk Gene Therapy. <i>Current Pharmaceutical Design</i> , 2002, 8, 1435-1450.	1.9	19
116	Unexpected substituent effects in the labeling of fluoroquinolone antimicrobial agents with fluorine- <sup>18</sup> . <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S892.	1.0	0
117	Labeling of cyclooxygenase-2 inhibitors DuP-697 and its desbromo derivative: The crucial role of the solvent. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S933.	1.0	0
118	The use of a zymark robotic system as a multitracer synthesizer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S1037-S1039.	1.0	0
119	Survey of fluorine- <sup>18</sup> labeled synthons as alkylating agents for the radiolabeling of (OLIGO)nucleotides. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, S148.	1.0	1
120	Drug development, radiolabeled drugs and PET. <i>Annals of Medicine</i> , 1999, 31, 432-437.	3.8	18
121	Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D <sub>2</sub> and Histamine H <sub>3</sub> Receptors: A PET Study in Healthy Rats. <i>Molecular Pharmaceutics</i> , 0, , .	4.6	0